$1.17
4.10% today
Nasdaq, Apr 03, 06:48 pm CET
ISIN
US5560991094
Symbol
MGNX
Sector
Industry

MacroGenics, Inc. Stock price

$1.22
-1.06 46.49% 1M
-2.31 65.44% 6M
-2.03 62.46% YTD
-12.09 90.83% 1Y
-8.77 87.79% 3Y
-4.19 77.45% 5Y
-30.42 96.14% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.00 0.00%
ISIN
US5560991094
Symbol
MGNX
Sector
Industry

Key metrics

Market capitalization $76.97m
Enterprise Value $-87.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.21
EV/Sales (TTM) EV/Sales -0.58
P/S ratio (TTM) P/S ratio 0.51
P/B ratio (TTM) P/B ratio 0.66
Revenue growth (TTM) Revenue growth 155.26%
Revenue (TTM) Revenue $149.96m
EBIT (operating result TTM) EBIT $-110.58m
Free Cash Flow (TTM) Free Cash Flow $-72.08m
Cash position $201.67m
EPS (TTM) EPS $-1.08
P/E forward negative
P/S forward 1.23
EV/Sales forward negative
Short interest 9.66%
Show more

Is MacroGenics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

MacroGenics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a MacroGenics, Inc. forecast:

3x Buy
38%
5x Hold
63%

Analyst Opinions

8 Analysts have issued a MacroGenics, Inc. forecast:

Buy
38%
Hold
63%

Financial data from MacroGenics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
150 150
155% 155%
100%
- Direct Costs 20 20
11% 11%
13%
130 130
218% 218%
87%
- Selling and Administrative Expenses 64 64
49% 49%
42%
- Research and Development Expense 170 170
8% 8%
113%
-103 -103
35% 35%
-69%
- Depreciation and Amortization 7.54 7.54
22% 22%
5%
EBIT (Operating Income) EBIT -111 -111
34% 34%
-74%
Net Profit -67 -67
639% 639%
-45%

In millions USD.

Don't miss a Thing! We will send you all news about MacroGenics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MacroGenics, Inc. Stock News

Neutral
Seeking Alpha
14 days ago
MacroGenics, Inc. (NASDAQ:MGNX ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants James Karrels - SVP, CFO and Secretary Scott Koenig - President and CEO Stephen Eck - SVP, Clinical Development & Chief Medical Officer Conference Call Participants Peter Lawson - Barclays Jonathan Chang - Leerink Partners Nicholas Lorusso - TD Cowen Jonathan Miller - Evercore ISI St...
Neutral
GlobeNewsWire
28 days ago
ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday,...
Neutral
Seeking Alpha
about one month ago
MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway int...
More MacroGenics, Inc. News

Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Head office United States
CEO Scott Koenig
Employees 341
Founded 2000
Website www.macrogenics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today